Characterization of a mutant Escherichia coli heat-labile toxin, LT(R192G/L211A), as a safe and effective oral adjuvant

Clinical and Vaccine Immunology

Volumn 18, Issue 4, 2011, Pages 546-551

  Norton, Elizabeth B ^a   Lawson, Louise B ^a   Freytag, Lucy C ^a   Clements, John D ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ARGININE; CYCLIC AMP; ESCHERICHIA COLI ENTEROTOXIN; ESCHERICHIA COLI HEAT LABILE ENTEROTOXIN; ESCHERICHIA COLI HEAT LABILE ENTEROTOXIN ANTIBODY; GLYCINE; IMMUNOGLOBULIN G ANTIBODY; TETANUS TOXOID; TETANUS TOXOID ANTIBODY; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; ENTEROTOXIGENIC ESCHERICHIA COLI; ENZYME ACTIVITY; ESCHERICHIA COLI; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; AMINO ACID SUBSTITUTION; ANIMALS; ANTIBODIES, BACTERIAL; ANTITOXINS; BACTERIAL TOXINS; CACO-2 CELLS; ENTEROTOXINS; ESCHERICHIA COLI PROTEINS; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MUTANT PROTEINS; TETANUS TOXOID;

EID: 79954535010     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00538-10     Document Type: Article

References (41)

1. Banerjee, S., et al. 2002. Safety and efficacy of low dose Escherichia coli enterotoxin adjuvant for urease based oral immunisation against Helicobacter pylori in healthy volunteers. Gut 51:634-640. (Pubitemid 35216848)
2. Belyakov, I. M., et al. 2006. Impact of vaccine-induced mucosal high-avidity CD8+ CTLs in delay of AIDS viral dissemination from mucosa. Blood 107:3258-3264.
3. Cheng, E., L. Cardenas-Freytag, and J. D. Clements. 1999. The role of cAMP in mucosal adjuvanticity of Escherichia coli heat-labile enterotoxin (LT). Vaccine 18:38-49.
4. Clements, J. D., and R. A. Finkelstein. 1978. Demonstration of shared and unique immunological determinants in enterotoxins from Vibrio cholerae and Escherichia coli. Infect. Immun. 22:709-713.
5. Clements, J. D., and R. A. Finkelstein. 1978. Immunological cross-reactivity between a heat-labile enterotoxin(s) of Escherichia coli and subunits of Vibrio cholerae enterotoxin. Infect. Immun. 21:1036-1039.
6. Clements, J. D., and R. A. Finkelstein. 1979. Isolation and characterization of homogeneous heat-labile enterotoxins with high specific activity from Escherichia coli cultures. Infect. Immun. 24:760-769.
7. Clements, J. D., N. M. Hartzog, and F. L. Lyon. 1988. Adjuvant activity of Escherichia coli heat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens. Vaccine 6:269-277.
8. Dickinson, B. L., and J. D. Clements. 1995. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect. Immun. 63:1617-1623.
9. Douce, G., et al. 1995. Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants. Proc. Natl. Acad. Sci. U. S. A. 92:1644-1648.
10. DuBois, A. B., L. C. Freytag, and J. D. Clements. 2007. Evaluation of combinatorial vaccines against anthrax and plague in a murine model. Vaccine 25:4747-4754.
11. Elson, C. O. 1989. Cholera toxin and its subunits as potential oral adjuvants. Curr. Top. Microbiol. Immunol. 146:29-33.
12. Field, M. 2003. Intestinal ion transport and the pathophysiology of diarrhea. J. Clin. Invest. 111:931-943.
13. Forster, M. L., et al. 2006. Protein disulfide isomerase-like proteins play opposing roles during retrotranslocation. J. Cell Biol. 173:853-859.
14. Freytag, L. C., and J. D. Clements. 2005. Mucosal adjuvants. Vaccine 23:1804-1813.
15. Gerber, S., et al. 2001. Human papillomavirus virus-like particles are efficient oral immunogens when coadministered with Escherichia coli heat-labile enterotoxin mutant R192G or CpG DNA. J. Virol. 75:4752-4760. (Pubitemid 32381518)
16. Glynn, A., et al. 2005. Protection against aerosolized Yersinia pestis challenge following homologous and heterologous prime-boost with recombinant plague antigens. Infect. Immun. 73:5256-5261.
17. Kotloff, K. L., et al. 2001. Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection. Infect. Immun. 69:3581-3590.
18. Lee, S., et al. 2010. Development of a Bacillus subtilis-based rotavirus vaccine. Clin. Vaccine Immunol. 17:1647-1655.
19. Lencer, W. I., et al. 1995. Targeting of cholera toxin and Escherichia coli heat labile toxin in polarized epithelia: role of COOH-terminal KDEL. J. Cell Biol. 131:951-962.
20. Levine, M. M., J. B. Kaper, R. E. Black, and M. L. Clements. 1983. New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development. Microbiol. Rev. 47:510-550.
21. Lewis, D. J., et al. 2009. Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS One 4:e6999.
22. Lu, X., J. D. Clements, and J. M. Katz. 2002. Mutant Escherichia coli heat-labile enterotoxin [LT(R192G)] enhances protective humoral and cellular immune responses to orally administered inactivated influenza vaccine. Vaccine 20:1019-1029.
23. Lu, Y. J., et al. 2010. Options for inactivation, adjuvant, and route of topical administration of a killed, unencapsulated pneumococcal whole-cell vaccine. Clin. Vaccine Immunol. 17:1005-1012.
24. McNeal, M. M., et al. 2007. IFN-gamma is the only anti-rotavirus cytokine found after in vitro stimulation of memory CD4+ T cells from mice immunized with a chimeric VP6 protein. Viral Immunol. 20:571-584.
25. Merritt, E. A., et al. 1994. Structure of partially-activated E. coli heat-labile enterotoxin (LT) at 2.6 Å resolution. FEBS Lett. 337:88-92.
26. Michetti, P., et al. 1999. Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults. Gastroenterology 116:804-812. (Pubitemid 29153528)
27. Mutsch, M., et al. 2004. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N. Engl. J. Med. 350:896-903.
28. Oplinger, M. L., et al. 1997. Abstr. 37th Intersci. Conf. Antimicrob. Agents Chemother., abstr. G-10. American Society for Microbiology, Washington, DC.
29. Pizza, M., et al. 1994. A genetically detoxified derivative of heat-labile Escherichia coli enterotoxin induces neutralizing antibodies against the A subunit. J. Exp. Med. 180:2147-2153.
30. Quan, F. S., et al. 2009. Kinetics of immune responses to influenza virus-like particles and dose-dependence of protection with a single vaccination. J. Virol. 83:4489-4497.
31. Schmitz, A., H. Herrgen, A. Winkeler, and V. Herzog. 2000. Cholera toxin is exported from microsomes by the Sec61p complex. J. Cell Biol. 148:1203-1212.
32. + T cells with protection against rotavirus shedding in mice intranasally immunized with VP6 and the adjuvant LT(R192G). J. Virol. 81:3740-3748.
33. Steinsland, H., et al. 2003. Protection from natural infections with enterotoxigenic Escherichia coli: longitudinal study. Lancet 362:286-291. (Pubitemid 36936840)
34. Summerton, N. A., et al. 2010. Toward the development of a stable, freeze-dried formulation of Helicobacter pylori killed whole cell vaccine adjuvanted with a novel mutant of Escherichia coli heat-labile toxin. Vaccine 28:1404-1411.
35. Teter, K., R. L. Allyn, M. G. Jobling, and R. K. Holmes. 2002. Transfer of the cholera toxin A1 polypeptide from the endoplasmic reticulum to the cytosol is a rapid process facilitated by the endoplasmic reticulum-associated degradation pathway. Infect. Immun. 70:6166-6171.
36. Teter, K., M. G. Jobling, D. Sentz, and R. K. Holmes. 2006. The cholera toxin A1(3) subdomain is essential for interaction with ADP-ribosylation factor 6 and full toxic activity but is not required for translocation from the endoplasmic reticulum to the cytosol. Infect. Immun. 74:2259-2267.
37. Tribble, D. R., S. Baqar, and S. A. Thompson. 2008. Development of a human vaccine, p. 429-444. In I. Nachamkin, C. M. Szymanski, and M. J. Blaser (ed.), Campylobacter, 3rd ed. ASM Press, Washington, DC.
38. Tsai, B., C. Rodighiero, W. I. Lencer, and T. A. Rapoport. 2001. Protein disulfide isomerase acts as a redox-dependent chaperone to unfold cholera toxin. Cell 104:937-948.
39. Tumpey, T. M., M. Renshaw, J. D. Clements, and J. M. Katz. 2001. Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection. J. Virol. 75:5141-5150.
40. Uddowla, S., L. C. Freytag, and J. D. Clements. 2007. Effect of adjuvants and route of immunizations on the immune response to recombinant plague antigens. Vaccine 25:7984-7993.
41. Zhu, X., et al. 2001. ARF binds the C-terminal region of the Escherichia coli heat-labile toxin (LTA1) and competes for the binding of LTA2. Biochemistry 40:4560-4568. (Pubitemid 32374644)